1
New study to test Sema3A antibody in rare genetic kidney disease
Evotec SE has announced that partner Bayer AG has initiated a phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting Semaphorin-3A (Sema3A), as a potential treatment for Alport syndrome.
The programme stems from a multi-target research collaboration between the two companies in kidney diseases. Evotec is set to receive a milestone payment upon first patient dosing, expected in early 2026.
Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension…